Heterologous Expression of Biopreservative Bacteriocins With a View to Low Cost Production

Abstract

Bacteriocins, a heterogenous group of antibacterial ribosomally synthesized peptides, have potential as bio-preservatives in in a wide range of foods and as future therapeutics for the inhibition of antibiotic-resistant bacteria. While many bacteriocins have been characterized, several factors limit their production in large quantities, a requirement to make them commercially viable for food or pharma applications. The identification of new bacteriocins by database mining has been promising, but their potential is difficult to evaluate in the absence of suitable expression systems. E. coli has been used as a heterologous host to produce recombinant proteins for decades and has an extensive set of expression vectors and strains available. Here, we review the different expression systems for bacteriocin production using this host and identify the most important features to guarantee successful production of a range of bacteriocins.

Molecular Characterization and Heterologous Production of the Bacteriocin Peocin, a DNA Starvation/Stationary Phase Protection Protein, from Paenibacillus ehimensis NPUST1

“…Based on the criteria of classification, the heat-stable peocin bacteriocin with molecular weight of 17588.4 Da is considered as Class III bacteriocin. Diverse bacteriocins expressed by recombinant E. coli have been studied and reviewed [17]. In the present study, the highest bacteriocin yield was obtained with fed-batch cultures of E. coli BL21 (DE3)/pET-peocin in a 5 L controlled bioreactor (Table 3).…”

“…The use of Escherichia coli as a cell factory provides an excellent platform for the expression of heterologous prokaryotic proteins. The well-established tools for the E. coli expression system, such as a variety of expression plasmids, a vast number of engineered strains, and many cultivation strategies, are easily accessible, and thus, this species is the most commonly used species for bacteriocin expression [17]. Recently, a report showed that the production yield of BtCspB, a novel cold-shock-like bacteriocin from Bacillus thuringiensis , by heterologous expression in recombinant E. coli significantly increased 449 times, supporting the use of E. coli as an effective system for bacteriocin production [18].…”

Ocins for Food Safety

“…Therefore, it is important to explore innovative ways of ocin production, e.g., via genetically engineered microorganisms such as E. coli and Lactococcus lactis . Between these microorganisms, E. coli is preferred because its genetic system is understood and can be exploited for the expression of any gene of interest (Beatriz et al, 2018). Even though several different expression hosts have been identified, BL21 DE3 and the plasmid pET are optimum (Studier and Moffatt, 1986; Rosenberg et al, 1987; Studier et al, 1990).…”

“…Therefore, it is important to exercise caution when selecting the promoter. Mesa-Pereira et al (2018) discussed the production of ocins in heterologous hosts.…”

Mining, heterologous expression, purification, antibactericidal mechanism, and application of bacteriocins: A review

“…To our knowledge, although there have been a few reviews about classification (Mokoena, 2017), screening (Zou, Jiang, Cheng, Fang, & Huang, 2018), heterologous expression (Mesa‐Pereira, Rea, Cotter, Hill, & Ross, 2018), purification (Jamaluddin, Stuckey, Ariff, & Wong, 2018), and applications (Lopez‐Cuellar, Rodriguez‐Hernandez, & Chavarria‐Hernandez, 2016) of bacteriocins, this is a more comprehensive review of the scientific knowledge on bacteriocins, mainly related to six parts: (a) classification of bacteriocins; (b) mining methods; (c) heterologous expression strategies; (d) purification and identification of bacteriocins; (e) antibacterial mechanism; and (f) application examples of bacteriocins in fruits and vegetables products, dairy products, and meat products. This review will give readers a clear understanding of bacteriocins and help them think about further research scope in bacteriocins.…”